Brokers Offer Predictions for ACRS FY2027 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for Aclaris Therapeutics in a research note issued to investors on Monday, March 16th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will earn ($0.55) per share for the year. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.

A number of other brokerages also recently issued reports on ACRS. Wall Street Zen downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Craig Hallum started coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.80.

Aclaris Therapeutics Stock Performance

ACRS opened at $3.74 on Tuesday. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89. The company has a market cap of $451.04 million, a P/E ratio of -7.06 and a beta of 0.88. The business’s 50-day simple moving average is $3.33 and its 200-day simple moving average is $2.73.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. boosted its position in shares of Aclaris Therapeutics by 409.0% in the 1st quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 45,864 shares during the period. Millennium Management LLC increased its position in Aclaris Therapeutics by 111.0% during the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock worth $6,325,000 after buying an additional 2,175,101 shares during the period. Goldman Sachs Group Inc. increased its position in Aclaris Therapeutics by 29.7% during the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock worth $851,000 after buying an additional 127,366 shares during the period. ProShare Advisors LLC purchased a new stake in Aclaris Therapeutics in the second quarter valued at approximately $26,000. Finally, Geode Capital Management LLC lifted its stake in Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after buying an additional 1,282,042 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.